Here you can find the life-saving research projects that have been funded by the Leukaemia Foundation.

If you require more information about a particular project than what is listed below, please contact us.

2019

• Improving therapy for CRLF2-rearranged Ph-like acute lymphoblastic leukemia, Dr Charles Mulligan, St Jude Children’s Research Hospital (Memphis, US)
• Beyond Azacitidine: Investigating new therapeutic strategies for the treatment of MDS, Dr Ashwin Unnikrishnan, University of NSW (Sydney)
• Therapeutic targeting of IRF4 to treat multiple myeloma, Professor Stephen Nutt, Walter & Eliza Hall Institute of Medical Research (Melbourne)
• Targeting deregulated epigenetic mechanisms in B-cell lymphomas, Professor Ricky Johnstone, University of Melbourne (Melbourne)
• T-cell immunotherapy for B-cell malignancies and viral infections, Dr Wei Jiang, Westmead Cellular Therapies Group (Sydney)
• Using genetic and molecular technologies to better understand follicular lymphoma, Dr Karthik Nath, The Mater Research Institute (Brisbane)
• Investigating the mechanisms by which Tp53 prevents the development of leukaemia, lymphoma, Elizabeth Lieschke, Walter and Eliza Hall Institute of Medical Research (Melbourne)

2018

• Novel drug for treatment of Burkitt’s lymphoma, Professor Andreas Strasser and Dr Gemma Kelly, Walter and Eliza Hall Research Institute (Melbourne)

2015

•  Obinutuzumab (CLL7 study), Stephen Mulligan, Royal North Shore Hospital, ALLG, Grant-in-Aid
• Survivorship in Blood Cancer, Pam McGrath, University of Noter Dame Australia, Grant-in-Aid
• How do the functional interaction between pro-survival MCL-1, proapoptotic BIM and the tumour suppressor P53 affect the development, sustained growth and therapeutic responses of leukaemia and lymphoma? Stephanie Gradbow, WEHI, Post-Doctoral Fellowship
• Epigenetic targeting of leukaemia stem cells, Omer Gilan, Peter Mac, Post-doctoral Fellowship
• Designing protein-protein interaction modulator for anti-leukaemia therapy, Jessica Holien, St Vincent’s Hospital, Post-Doctoral Fellowship
• The involvement of class I and class II mutations in the onset and progression of AML, Andrea Newbold, Peter Mac, Post-Doctoral Fellowship
• Net humoral immunity and its impact on outcome in lymphoma, Colm Keane, Princess Alexandra Hospital, Career Establishment Grant
• Investigating the role of BLIMP1/PRDM1 and XBP1 as potential tumour suppressors in multiple myeloma, Pasquale Fedele, WEHI, Clinical PhD Scholarship
• Generating genetically modified CAR T cells to treat haematological malignancies, Ming-Celine Dubosq, Clinical PhD Scholarship
• Targeting regulator of natural killer cell homeostasis in leukaemia immunotherapy, Rebecca Delconte, WEHI, PhD Scholarship
• What factors drive immune response in AML, Rebecca Austin, QIMR Berghofer, PhD Scholarship
• Assessing the efficacy and toxicities of a novel MCL-1 inhibitor in mouse and human pre-clinical models, Margs Brennan, WEHI, PhD Scholarship
• Circulating tumour DNA for monitoring treatment responses and resistance in CLL, Elise Wallach, Peter Mac, PhD Scholarship
• Visualising the mechanism of action of epigenetic therapies in MDS, Dean Tyler, Peter Mac, PhD Scholarship
• A genomic approach to understanding clonal evolution and disease transition in myeloma, Ankit Dutta, SAHMRI, PhD Scholarship

2014

• Accurate BCR-ABL1 compound mutation detection to examine their role in drug resistance, Wendy Parker, University of SA, Grant-in-Aid
• SF3B1-associated back-splicing of genes in myelodysplasia and CLL, Timothy Mercer, Garvan Institute, Grant-in-Aid
• Combining vaccination and antibody-based immunotherapy to treat B cell lymphomas, Stephen Mattarollo, Diamantina Institute, Grant-in-Aid
• IL-17 mediated mobilisation of haematopoietic stem and progenitor cells, Steven Lane, QIMR Berghofer, Grant-in-Aid
• Development of a genetic risk score that predicts response to hypo methylating agents in MDS, Meghan Wall, St Vincent’s Hospital, Grant-in-Aid
• Developing a national survivorship care plan for survivors of childhood blood cancer, Jordana McLoone, Sydney Children’s Hospital, Grant-in-Aid
• Exploring cic-regulatory mutation in AML, Jason Wong, Lowe Cancer Research Centre, University of NSW, Grant-in-Aid
• Genomic profiling to define therapy resistance mechanisms in myeloid leukaemia, Ian Majweski, WEHI, Grant-in-Aid
• Thrombopoietin signalling in lymphoid cancer, Emma Josefsson, WEHI, Grant-in-Aid
• Targeting IL-7 signalling pathway in T-Cell ALL, Cedric Tremblay, Monash University, Grant-in-Aid
• The role of C-Cbl in regulation the development of AML, Carolyn Grove, University of WA, Grant-in-Aid
• Impact of deregulated HOXA1 in MDS, Shuh Ying Tan, St Vincent’s Hospital, Clinical PhD Scholarship
• Combination therapies with the novel POL I transcription inhibitor for the treatment of highly refractory haematological malignancies, Kylee MacLachlan, University of Melbourne, Clinical PhD Scholarship
• Cellular therapies for B cell malignancies and post-transplant viral infections, David Bishop, Westmead, Clinical PhD Scholarship
• Characterising genetic factors that contribute to relapses in AML, Chen Hsung Edward Chew, University of Melbourne, Clinical PhD Scholarship
• Determining the role of the pro-survival Bcl-2 family member A2 in Lymphoma and leukaemia, Robyn Schenk, WEHI, PhD Scholarship
• Role of dynein light chain in B cell lymphoma onset and therapies, Lingli Li, St Vincent’s Hospital, PhD Scholarship
• Cellular and molecular mediators of chronic GVHD, Katie Lineburg, QIMR Berghofer, PhD Scholarship
• The molecular basis of Fanconi Anaemia, a leukaemia predisposition syndrome, Julian O’Rourke. St Vincent’s Hospital, PhD Scholarship
• Investigating pre-existing and/or acquired resistance to novel Pol I transcription inhibitors for the treatment of hematologic malignancies, Donald Cameron, Peter Mac, PhD Scholarship
• Graft v Host disease, Katie Lineburg, QIMR Berghofer Medical Research Institute (Brisbane)
• Boosting the immune system response, Dr Stephen Mattarollo, The University of Queensland Diamantina Institute (Brisbane)
• Targeting stem cells in myeloproliferative disorders, Dr Steven Lane

2013

• Targeting telomerase to eradicate leukaemia stem cells in AML, Stephen lane, QIMR Berghofer, Grant-in-Aid
• Role of pro-survival BCL-2 proteins in AML, T-All and CML, Stefan Glaser, WEHI, Grant-in-Aid
• Blood Cancer Survivorship, Pam McGrath, University of Noter Dame Australia, Grant-in-Aid
• Pilot study to look at the feasibility of using remote vital sign monitoring app to improve the care of patients being treated at home with highly myelosuppressive chemotherapy, Nigel Waterhouse, The Mater, Grant-in-Aid
• Targeting stem cells in mouse model of T-cell ALL, Matthew McCormack, WEHI, Grant-in-Aid
• MLL fusion proteins: uncovering genetic and epigenetic mechanisms of leukemogenesis, Margherita Ghisi, Peter Mac, Grant-in-Aid
• Chair in Blood Cancer Research, Maher Gandhi, University of Queensland, Diamantina Institute, Grant-in-Aid
• Regulation of B cell survival and migration by the oncogene c-Myb, Kim Jacobson, WEHI, Grant-in-Aid
• Off the shelf T-cell expressing a chimeric antigen receptor targeting B-cell tumours, Kenneth Micklethwaite, Westmead, Grant-in-Aid
• Childhood Ph-like ALL: improving diagnostic screening and therapeutic rationale, Deb White, SAHMRI, Grant-in-Aid
• Elucidation of the mechanisms involved in the development of erytho-megakaryocytic leukaemia driven by the proto-oncogene ETS-related gene ERG, Catherine Carmichael, WEHI, Grant-in-Aid
• Identifying drivers of a stem cell-like program in leukaemic cells, Ashwim Innikrishnan, University of NSW, Grant-in-Aid
• Targeting the pro-survival machinery in AML for therapeutic benefit, Andrew Wei, Alfred Hospital, Grant-in-Aid
• Characterisation of immune response in CML patient on nilotinib and interferon alpha, Agnes Yong, SAHMRI, Grant-in-Aid
• Assessment of a genetic signature to predict CML disease progression, Wendy Parker, Centre for Cancer Biology, Post-Doctoral Fellowship
• Targeting disease-initiating cells in Jak2V617F MPN’s, Steven Lane, QIMR Berghofer, Post-Doctoral Fellowship
• Structural investigation of interleukin-3 receptor signalling for AML therapeutics, Sophie Broughton, St Vincent’s Hospital, Post-Doctoral Fellowship
• Exploiting novel mutations in high risk childhood acute leukaemia with targeted therapy, Santi Suryani, Children’s Cancer Institute, Post-Doctoral Fellowship
• Mechanisms of antigen presentation following bone marrow transplantation GVHD, Moto Koyama, QIMR Berghofer, Post-Doctoral Fellowship
• Targeting epigenetic regulators in AML, Mark Dawson, Peter Mac, Senior Research Fellowship
• Defining the role of LYL1 and NG-kappaB in T-cell ALL, Sung Kai Chiu, Monash University, Clinical PhD Scholarship
• Investigating myeloid microenvironment effects on the epigenetic control of CD4+ T cell polarisation, Rachel Cooke, University of Melbourne, Clinical PhD Scholarship
• Regulation of MCL1 transcription and protein stability in myeloma and lymphoma cells, Michael Sze Yuan Low, University of Melbourne, Clinical PhD Scholarship
• Therapeutic targeting of CDK9 and immune evasion in MYC-driven B-cell lymphoma, Gareth Gregory, Peter Mac, Clinical PhD Scholarship
• Chromatin regulation of self-renewal in leukaemia cells, Chun Yew Fong, Peter Mac, Clinical PhD Scholarship
• Determining the role of mutant p53 in sustained growth and MYC-driven lymphomas, Brandon Aubrey, WEHI, Clinical PhD Scholarship
• Cytotoxic immune cells for anti-viral / tumour therapy in haematological malignancy, Barbara Withers, Westmead, Clinical PhD Scholarship
• Anti-leukaemia effects of the type I and II interferons (GVHD), Andrea Henden, QIMR, Clinical PhD Scholarship
• Assessment of biomarkers of response and the development of novel treatment strategies to improve molecular response in CML, David Yeung, SA Pathology, Clinical PhD Scholarship
• Regulators of epigenetic gene expression in haematopoiesis and leukaemia, Therese Vu, QIMR Berghofer, PhD Scholarship
• Combined epigenetic and immunomodulatory therapy for MYC-driven lymphoma and myeloma, Simon Hogg, Peter Mac, PhD Scholarship
• Roles of NF-kappa B transcription factors in AML, Hui Peng Lim, Monash University, PhD Scholarship
• Mutation profiling of megakaryocytes in MPN, Jacques Malherbe, University of WA, Honours Scholarship
• Dysregulated cell signalling in megakaryocytes in MPN’s, Ayesha Arshad, University of WA, Honours Scholarship
• Investigating factors that may cause genetic changes in leukaemia
• Double discovery – game changer in quest to cure leukaemia

2012

• Is elevated N-cadherin expression a poor prognostic indication in myeloma patients, Andrew Zannettino, University of Adelaide, Grant-in-Aid
• The role of PI3CA mutation in driving haematological malignancy, Wayne Phillips, Peter Mac, Grant-in-Aid
• Targeted disease-initiating stem cells in MPN, Steveb Lane, QIMR Berghofer, Grant-in-Aid
• RNA polymerase I as a new target for the treatment of haematological malignancies, Ross Hannan, Peter Mac, Grant-in-Aid
• Finding new therapeutics to target T cell leukaemia initiating cells, Matthew McCormack, WEHI, Grant-in-Aid
• The role of the pro-survival BLC-2 family member A1 in the development of lymphomas, Marco Herold, WEHI, Grant-in-Aid
• The immunopathogenesis of EBV-positive diffuse large B-cell lymphoma of the elderly, Maher Gandhi, QIMR Berghofer, Grant-in-Aid
• Generic variation and risk of infection in children following stem cell transplant, Lesley Ashton, Lowe Cancer Research Centre, University of NSW, Grant-in-Aid
• Evaluating the efficacy and tolerability of targeting pro-survival Mcl-1 in vivo, Kylie Mason, WEHI, Grant-in-Aid
• Retinoid signalling in T-cell development and Leukaemia, David Izon, St Vincent’s Hospital, Grant-in-Aid
• Role of CD123 in MDS and AML, Angel Lopez, SA Pathology, Grant-in-Aid
• Predicting clinical success of a novel inhibitor of ribosomal RNA synthesis, Megan Bywater, Peter Mac, Post-Doctoral Fellowship
• Quality of care in blood cancer: patients perceptions, Flora Tzelepis, University of Newcastle, Post-Doctoral Fellowship
• The role of Erg Transcription factor in the development of l leukaemia, Sophie Hye Suk Lee, WEHI, Clinical PhD Scholarship
• T-cell therapy for infection and cancer prevention post allogenic stem cell transplant, Chun Kei Kris Ma, Westmead, Clinical PhD Scholarship
• Therapeutic studies to target signal transduction pathways in AML, Peter Tan, Monash University, Clinical PhD Scholarship
• Molecular determinants of nilotinib treatments in patients with CML, Jane Gordon, Centenary Institute, Clinical PhD Scholarship
• Investigating myeloma microenvironment effects on t cell polarisation and function, Nicholas Gheradin, Peter Mac, PhD Scholarship
• Optimisation of CD8+ dendritic cells cross presentation for enhances graft vs leukaemia effects following transplant, Melody Cheoung Shuk Shien, QIMR Berghofer, PhD Scholarship
• The role of Ikaros in ALL treatment resistance, Matthew Witowski, WEHI, PhD Scholarship
• Conceptualising meaning in life: the experience of young adult cancer survivors, Danielle Tindle, Queensland University of Technology, PhD Scholarship
• The role of ADAR1 in haematopoiesis and leukaemia, Brian Liddicoat, St Vincent’s Hospital, PhD Scholarship
• The role of the bone marrow microenvironment in the myeloma plasma cell dormancy and reactivation – toward a cure for myeloma; Prof Andrew Zannettino (SAHMRI), Prof Peter Croucher (Garvan Institute), Dr Kyohei Nakamura (QIMR Berghofer)

2011

• The role of Gpsm2 in self-renewal of haematopoietic and leukaemia stem cells, Sarah Russell, Peter Mac, Grant-in-Aid
• Epigenetic profiling of B-cell lymphoma progression and response to HDACi treatment, Ross Tothill, Peter Mac, Grant-in-Aid
• Predicting the in vivo sensitivity of paediatric acute lymphoblastic leukaemia to BH-3 mimetic drugs (ABT-263 Navitoclax), Richard Lock, Children’s Cancer Institute, Grant-in-Aid
• Dequalinium chloride as a targeted therapy for AML, Richard D’Andrea, Centre for Cancer Biology, Grant-in-Aid
• Patterns of differentially abundant proteins on progressive CLL, Richard Christopherson, University of Sydney, Grant-in-Aid
• Phase III randomised trial of Melphalan and Dexamethasone =/- Bortezomib in AL Amyloidosis, Peter Mollee, ALLG, Grant-in-Aid
• Contribution of apoptosis to clearance of haematopoietic malignancies by cytotoxic lymphocytes, Nigel Waterhouse, The Mater, Grant-in-Aid
• The role of thymic self-renewal in causing T cell acute lymphoblastic leukaemia, Matthew McCormack, WEHI, Grant-in-Aid
• Targeting novel cell survival programs in AML regulated by PI3-K, Mark Guthridge, Centre for Cancer Biology, Grant-in-Aid
• Identification of susceptibility genes for familial haematological malignancies, Joanne Dickinson, Menzies Research Institute, University of Tasmania, Grant-in-Aid
• Immune suppression in GVHD, Geoff Hill, QIMR Berghofer, Grant-in-Aid
• Developing a gene signature to predict the optimal front line kinase inhibitor for CP-CML patients, Deb White, SA Pathology, Grant-in-Aid
• Autologous cellular therapy for rapid immune reconstitution in patient with CLL receiving immunosuppressive chemotherapy, David Gottlieb, Westmead, Grant-in-Aid
• Small molecule inhibitors of protein arginine methyltransferase 5 (PRMT5) for CLL, David Curtis, Royal Melbourne Hospital, Grant-in-Aid
• Improving prognostic analysis of CLL through assessment of DNA repair, Bryone Kuss, Flinders Medical Centre, Grant-in-Aid
• Impaired double strand break repair as a mechanism of relapse following chemotherapy, Bryone Kuss, Flinders Medical Centre, Grant-in-Aid
• Inositol phosphoinositide regulation of PI3-K activity: defining their role as collaborators in leukaemogenesis, Andrew Wei, Monash University, Grant-in-Aid
• AML, M16 phase 2 randomised study investigating the FLT3 inhibitor Srafenib in sequence after intensive chemotherapy for untreated adult AML harbouring FLT3 mutations, Andrew Wei, Alfred Hospital, Grant-in-Aid
• Genetic co-cooperativity and the role of transcription factors in malignant haematological disorders, Ashley Ng, WEHI, Post-Doctoral Fellowship
• The role of sotepontin as a cell survival factor in AML, Tse-Chieh The, Monash University, Clinical PhD Scholarship
• Therapeutic inhibition of the cell cycle checkpoints mediated by CHK1, Jake Shortt, Peter Mac, Clinical PhD Scholarship
• Ineffective haematopoiesis and the role of apoptosis in MDS, Andrew Guirguis, Monash University, Clinical PhD Scholarship
• The role of IL-3 receptor on AML stem cells, Nicole Christie, SA Pathology, PhD Scholarship
• Impact of MCL-1 on the dev of AML and its resistance to therapy, Natasha Anstee, WEHI, PhD Scholarship
• Cooperating oncogenic lesions in Myc driven lymphoma, Marcus Lefebure, Peter Mac, PhD Scholarship
• Inhibiting the PI3K pathway induces B-cell lymphoma death via ribosome biogenesis, Jenifer Devlin, Peter Mac, PhD Scholarship
• Roles of the bone marrow microenvironment in the regulation of blood disease, Hui Peng Lim, University of Melbourne, PhD Scholarship
• MLF1 regulation of the haematopoietic stem cell compartment, Tara Nababan, University of WA, Honours Scholarship

2010

• Study of genes that cause CLL, Steven Fuller, SA Pathology, Grant-in-Aid
• Understanding how blood and leukaemia stem cells function, Stephen Ting, Peter Mac, Grant-in-Aid
• Regulation of VEGF on human Dendritic cells in multiple myeloma infiltrated bone marrow, Slavica Vuckovic, The Mater, Grant-in-Aid
• A new CLL model that aids better understanding of disease and how to treat it effectively, Paul Neeson, Peter Mac, Grant-in-Aid
• Blocking HOX genes to treat leukaemia, Paul Ekert, Murdoch Children’s Research Institute, Grant-in-Aid
• Helping blood cell number recover after transplantation or chemotherapy, Louise Purton, St Vincent’s Hospital, Grant-in-Aid
• Promoting cell death to improve treatment of CLL (Navitoclax), Kylie Mason, WEHI, Grant-in-Aid
• Randomised phase III trial to assess response adapted therapy using PET in newly diagnosed advanced HL, John Seymour, Peter Mac, Grant-in-Aid
• Do leukemic cells adopt blood stem cell properties to induce leukaemia? John Pimanda, University of NSW, Grant-in-Aid
• Methods to prevent GVHD after transplantation, Hannah Cullup, The Mater. Grant-in-Aid
• A novel agent targeting the HSP90 protein in CLL, Giles Best, Royal North Shore Hospital and University of Sydney, Grant-in-Aid
• Novel growth factors in CLL, Devender Gill, Princess Alexandra Hospital, Grant-in-Aid
• Using the immune system against CLL, David Ritchie, Peter Mac, Grant-in-Aid
• Definition of the mechanism by which caspase-2 suppresses lymphomagenesis, Christine Hawkins, La Trobe University, Grant-in-Aid
• The use of donor immune cells to fight viral infections in recipients of blood stem cell transplants, Emily Blyth, Westmead, Clinical Fellowship
• Restoring immunity against viruses after bone marrow transplantation, Diok-Keen-Tey, QIMR Berghofer, Clinical Fellowship
• Cell cycle regulation in haemopoietic stem cells and MDS, Carl Walkley, St Vincent’s Hospital, Clinical Fellowship
• Psychosocial outcomes in blood cancer: the role of treatment centre structures and processes, Tara Clinton-McHarg, University of Newcastle, Post-Doctoral Fellowship
• Understanding the molecular basis of lymphoma cell death, Mark McKenzie, WEHI, Post-Doctoral Fellowship
• The risk of haematopoietic cancer in people hospitalised with an autoimmune disease, Marina Van Leeuween, University of NSW, Post-Doctoral Fellowship
• New therapies for ALL, Craig Wallington Beddoe, Westmead, Clinical PhD Scholarship
• Identification of genetic changes in aggressive B-cell lymphomas and impact on tumour growth, Anna Johnston, John Curtin School of Medical Research ANU, Clinical PhD Scholarship
• Where to after treatment? A new way to support young people with cancer and their parents, Ursula Sanson-Daly, University of NSW, PhD Scholarship
• EpHA proteins may be therapy targets in Leukaemia, Sara Charmsaz, QIMR Berghofer, PhD Scholarship
• Eradication of leukaemic cells using therapy combination in CML, Lisa Schafranek, SA Pathology, PhD Scholarship
• Understanding the molecular mechanisms that regulate blood stem cell activity, Leila Varghese, WEHI, PhD Scholarship
• Targeting signalling in ALL, Jacky Wong, Westmead, PhD Scholarship
• Defining the unique characterises of CO-CML patients that reasons poorly to imatinib, Dale Watkins, SA Pathology, PhD Scholarship
• Analysis of therapeutic agents to kill leukaemia cells via notch signalling, Timothy Colgan, University of WA, Honours Scholarship
• Measurement of blood markers to determine cell therapy treatment of GVHD, Kaija Strautins, Royal Perth Hospital, Honours Scholarship
• Researchers identify gene that could lead to better understanding of MDS, Dr Carl Walkley, St Vincent’s Institute’s Stem Cell Regulation Unit (Melbourne)

2009

• Development of drugs to block the MYB cancer gene in human leukaemia, Tom Gonda, Diamantina Institute, Grant-in-Aid
• Role of myeloid leukaemia factor 1 in stem cells, Svend Klinken, University of WA, Grant-in-Aid
• Developing new treatments for blood cancer, Ricky Johnston, Peter Mac, Grant-in-Aid
• Determining the cause of T-cell ALL, Matthew McCormack, Royal Melbourne Hospital, Grant-in-Aid
• Understanding how blood cell disease form, Louise Perton, St Vincent’s Hospital, Grant-in-Aid
• The risk of developing a second cancer after leukaemia or lymphoma, Lin Fritshci, University of WA, Grant-in-Aid
• Susceptibility to chronic lymphocyte leukaemia in an extended family pedigree, James Wiley, University of Sydney, Grant-in-Aid
• Developing effective therapy for chronic GVHD, Geoff Hill, QIMR Berghofer, Grant-in-Aid
• Investigating the factors that cause and influence the outcome of childhood Leukaemias, David Ashley, Mordoch Children’s Research Institute, Grant-in-Aid
• Familial psychological adjustment and needs on childhood cancer treatment completion, Claire Wakefield, University of NSW, Grant-in-Aid
• Targeting increased PI3K and the bone marrow microenvironment for therapeutic benefit in leukaemia, Andrew Wei, Monash University, Grant-in-Aid
• Methods to precent GVHD after transplantation, Alison Rice, The Mater, Grant-in-Aid
• Bench to bedside – studies with a novel therapy in adult and childhood cancer, Seong Lin Khaw, WEHI, Clinical Fellowship
• New strategies to assist in the management of aggressive lymphoma, Colm Keane, Princess Alexandra Hospital, Clinical Fellowship
• Investigation of the physiological role of the transcriptional factor Erg in haematopoietic development and disease, Catherine Carmichael, WEHI, Post-Doctoral Fellowship
• Understanding and manipulating cell death to treat blood cancers, Erinna Faith Lee, WEHI, Post-Doctoral Fellowship
• Pathogenesis of MDS- identifying genes that are abnormally switched off in MDS, John Pimanda, University of NSW, Career Establishment Grant
• Mechanisms of drug resistance in childhood leukaemia, Vivek Bhadri, Children’s Cancer Institute of Australia, Clinical PhD Scholarship
• Understanding cancers of the blood, See Hend Pang, WEHI, PhD Scholarship
• Targeted modulation of antigen presenting cells in GVHD, Renee Robb, WIMR Berghofer, PhD Scholarship
• Molecular regulation of cell death and implications in platelet production, Michael White, WEHI, PhD Scholarship
• Novel disease markers and therapeutic targets in C-cell CLL, Melanie Sulda, Flinders University, PhD Scholarship
• Studies of cellular transport of nilotinib, Laura Eadie, Institute of Medical and Veterinary Science, PhD Scholarship
• New Strategies for the treatment and prevention of HL, Kimberly Jones, QIMR Berghofer, PhD Scholarship
• Genes involved in AML, Grace Liu, WEHI, PhD Scholarship
• To determine the role of Bok in programmed cell death and leukaemia development, Francine Ke, WEHI, PhD Scholarship
• The role of the innate immune system in cancer, Chris, Chan, Peter Mac, PhD Scholarship
• Study of a bone marrow stromal cell in CLL, Adrian Pannekoek, Royal Perth Hospital, Honours Scholoarship

2008

• Developing predictive assays to select second line therapy imatinib resistant CML, Tim Hughes, SA Pathology, Grant-in-Aid
• A new oncogene in AML and MDS, Ruth MacKinnon, St Vincent’s Hospital, Grant-in-Aid
• Improving treatment outcomes for infants with ALL, Michelle Henderson, Children’s Cancer Institute, Grant-in-Aid
• An analysis of AML in WA from 1991 to 2005, Mathew Wright, Royal Perth Hospital, Grant-in-Aid
• A novel mechanism of immunosuppression in B-cell lymphomas, Maher Gandhi, QIMR Berghofer, Grant-in-Aid
• Molecular Prognostication in Chronic Lymphocytic Leukaemia, Roy Banh, Princess Alexandra Hospital, Clinical Fellowship
• New therapeutic approach in acute leukaemia and transplant and GVHD, Simon Zhao-Xiong He, Royal Melbourne Hospital, Clinical Fellowship
• Developing a vaccine strategy to treat EBV-associated HL, Corey Smith, QIMR Berghofer, Post-Doctoral Fellowship
• Can the environment cause childhood leukaemia? If so how and when does this occur?, Nicholas Wong, Post-Doctoral Fellowship
• Gene trap mutagenesis a function screen to identify gene associated with glucocorticoid resistance in ALL, Scott Brown, Children’s Cancer Institute of Australia, PhD Scholarship
• Development of dendritic cell biomarker antibodies and application in leukaemia, Therese Seldon, The Mater, PhD Scholarship
• The impact of BH3-only genes on the response of murine lymphoma to anti-cancer therapy, Lind Happo, WEHI, PhD Scholarship
• Targeting MyB in human leukaemia, Diwakar Pattabiraman, University of Queensland, Diamantina Institute, PhD Scholarship
• Targeting a deregulated cell survival switch in CML cells, Hui Peng Lim, Institute of Medical and Veterinary Science, Honours Scholarship
• Role of DNAM-1 in NK Cell-Mediated Tumour Control, Chris Chan, Peter Mac, Honours Scholarship

2007

• Role of pentoxifylline (trental) on anaemia and hypoferritinaemia in myeloma, Stephanie P’ng, Grant-in-Aid
• Valproic acid and cytarabine therapy for elderly or relapsed AML, Peter Mollee, Princess Alexandra Hospital, Grant-in-Aid
• AML M13 – High dose Cytosine arabinose ) fludarabine without anthracycline for core-binding factor AML, Paula Marlton, ALLG, Grant-in-Aid
• Targeting drug resistance in childhood leukaemia, Maria Kavallaris, Children’s Cancer Institute, Grant-in-Aid
• Indirect antigen presentation and graft vs leukaemia effects after transplantation, Geoff Hill, QIMR Berghofer, Grant-in-Aid
• Improving the treatment of refectory GVDH using mesenchymal stromal cells, Stephen Larsen, Royal Prince Alfred Hospital, Career Establishment Grant
• Novel disease markers and therapeutic targets in B-cell CLL, Melanie Sulda, Flinders Unversity, PhD Scholarship
• Factors which control targeted drug uptake into CML cells, Jane Engler, Institute of Medical and Veterinary Science, PhD Scholarship
• Investigation of Klf5, a potentially new leukaemia causing gene, Subhobrata Das, Honours Scholarship
• Mesenchymal stem cells for allogeneic stem cell transplantation, Dana Ihdayhid, Royal Perth Hospital, Honours Scholarship

2006

• The effect of combining specific anti-cancer drug therapies as treatment for patients with leukaemia and lymphoma, Ricky Johnston, Peter Mac, Grant-in-Aid
• Molecular targeted therapy in childhood ALL, Richard Lock, Children’s Cancer Institute, Grant-in-Aid
• Genetic control of white blood cell production that may have a role in acute and chronic leukaemias, John Rasko, Centenary Institute of Cancer Medicine and Cell Biology, Grant-in-Aid
• A pooled analysis of studies for immune risk factors for NHL, Andrew Grulich, National Centre in HIV epidemiology and clinical research, Grant-in-Aid
• Blimp-1 regulated lymphocyte differentiation and leukaemogenesis, Axel Kallies, WEHI, Post-Doctoral Fellowship
• Targeted therapy and new diagnostic strategies for the management of the chronic MPD, William Stevenson, Royal North Shore Hospital, Career Establishment Grant
• Characterisation of leukaemic CML cells remaining after treatment, David Ross, Institute of Medical and Veterinary Science, Clinical PhD
• The role of lineage and maturity in determining in vitro sensitivity to kinase inhibitors in chronic phase CML, Jane Engler, Institute of Medical and Veterinary Science, Honours Scholarship

2005

• Amyloidosis Clinical Trial, Australasian Leukaemia and Lymphoma Group, Grant-in-Aid
• Glucocorticoid resistance mechanisms in childhood ALL, Richard Lock, Children’s Cancer Institute, Grant-in-Aid
• Mechanisms of drug resistance in AML, Leonie Ashman, University of Newcastle, Grant-in-Aid
• MicroRNA’s in primate haematopoiesis, John Rasko, Centenary Institute of Cancer Medicine and Cell Biology, Grant-in-Aid
• Development of anti-T ALL reagents, Jacqueline Matthews, University of Sydney, Grant-in-Aid
• The Australian familial haematological study, Graem Suthers, Women’s and Children’s Hospital, Grant-in-Aid
• Prevention of leukaemia relapse after stem cell transplantation, Geoff Hill, QIMR Berghofer, Grant-in-Aid
• Use of T-cells for immunotherapy of infections post-allogeneic stem cell transplant, Kenneth Micklethwaite, Westmead, Clinical Fellowship
• The role of apoptosis in suppression of myeloid Leukaemia by PU.1, Wendy Cook, Monash University, Post-Doctoral Fellowship
• Identification of oncogene from myeloid leukaemia by retroviral expressing cloning, Anna Brown, Women’s and Children’s Health Research Institute, Post-Doctoral Fellowship
• Assessing the apoptotic and therapeutic properties of histone deacetylases inhibitors in mouse models of cancer, Leigh Ellis, Peter Mac, PhD Scholarship
• Further definition of the tumour antigen targets of DC based immunotherapy in multiple myeloma, Jennifer Freeman, The Mater PhD Scholarship
• Potential new target molecules for AML treatment – the tole of the 35 -L5 molecule, Courtney Modra, The Mater, PhD Scholarship
• Proof of principle for the use of CTL induces by RNA loaded CD34+ stem cell derived DC to eradicate leukaemia post transplantation, Andy Hsu, The Mater, PhD Scholarship
• The role of the protein p202 in myeloid cell differentiation, Yi-No Ko, Peter Mac, Honour Scholarship
• The roles of FAM and beta-catenin in regulating the properties of some haemopoietic cells in vitro, Kate Jarman, Child Health Research Institute, Honours Scholarship
• The development of inhibitors of BCL-2-family proteins as potential therapeutic agents in leukaemia and lymphoma, Jessica Bird, James Cook University, Honours Scholarship
• The role of pRb in erythropoiesis, Catherine King, Peter Mac, Honours Scholarship

2004-2002

• Stratification of high risk ALL patients based on MRD, Murray Norris, Children’s Cancer Institute, Grant-in-Aid
• Molecular determinants of microtubule target drug response in childhood leukaemia, Maria Kavallaris, Children’s Cancer Institute, Grant-in-Aid
• Generation of immune anti-leukaemia effect using gene transfer to human leukaemia cells, David Gottlieb, Westmead, Grant-in-Aid
• Novel complexes of Gallium as potent anti-leukaemia and lymphoma agents, Des Richardson, Children’s Cancer Institute, Grant-in-Aid
• CD44v6 ligand involved in aggressiveness of Childhood ALL, Linda Bendall, Westmead, Grant-in-Aid
• Investigating the role of cell death inducing molecules in lymphoma and Leukaemia, Lisa Sedger, Westmead, Grant-in-Aid
• A genetic variation associated with CLL, James Wiley, Westmead, Grant-in-Aid